Antibody Clinical Trials in Beijing, Beijing Municipality
6 recruitingBeijing, Beijing Municipality, China
Showing 1–6 of 6 trials
Recruiting
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Advanced Hepatocellular CarcinomaBevacizumabAnti-PD1/PDL1 Antibody
Sun Yat-sen University240 enrolled1 locationNCT06323382
Recruiting
Phase 1
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Inflammatory Myopathy+5 more
China Immunotech (Beijing) Biotechnology Co., Ltd.12 enrolled1 locationNCT06978647
Recruiting
Phase 1Phase 2
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
Systemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisSjogren's Syndrome+6 more
Essen Biotech75 enrolled1 locationNCT06350110
Recruiting
A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy
MSS Metastatic Colorectal CancersMSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
Peking University Cancer Hospital & Institute50 enrolled1 locationNCT06549907
Recruiting
National, Multicentric Registry Study on Neuroimmunological Diseases in China
Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+3 more
Xuanwu Hospital, Beijing7,000 enrolled1 locationNCT06443333
Recruiting
Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
MicrobiomeImmune FunctionAnti-MDA5 Antibody Positive Dermatomyositis
Chinese PLA General Hospital50 enrolled1 locationNCT06203249